| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H32BrN6O3.Na |
| Molecular Weight | 675.55 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CN1C(=NC2=C1C=C(\C=C\C([O-])=O)C=C2)C3(CCC3)NC(=O)C4=CC5=C(C=C4)C(C6CCCC6)=C(N5C)C7=NC=C(Br)C=N7
InChI
InChIKey=YJADTGFGJMFOLM-KJEVSKRMSA-M
InChI=1S/C34H33BrN6O3.Na/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2;/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43);/q;+1/p-1/b13-9+;
Deleobuvir is a drug for the treatment of Hepatitis C, developed by Boehringer Ingelheim. Deleobuvir is a non-nucleoside HCV NS5B polymerase inhibitor that reversibly and noncovalently binds to the thumb pocket 1. It has shown rapid and strong antiviral activity when administered in combination with peginterferon-a2a and ribavirin. In 2014 Boehringer Ingelheim decided to halt further development of deleobuvir because preliminary analysis of phase 3 clinical trials indicated a low efficacy of the drug.
Originator
Approval Year
PubMed
Patents
ACTIVE MOIETY
SUBSTANCE RECORD
